about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Low-pro­file biotech led by Bris­tol My­ers vets grabs a suite of adeno­sine re­cep­tor an­tag­o­nists via tiny buy­out

3 years ago
R&D

Cy­tomX halts lead pro­gram and will seek a part­ner as breast can­cer drug dis­ap­points

3 years ago
R&D

Re­org com­ing for lit­tle biotech as it shut­ters PhII ra­dioim­munother­a­py tri­al on un­der­whelm­ing da­ta

3 years ago
R&D

Boehringer In­gel­heim, Evotec band with di­ag­nos­tics play­er to tack­le 'su­per­bugs' through joint ven­ture

3 years ago
Financing
Startups

Bruised Sy­ros scores $130M PIPE from mar­quee group — while grab­bing $60M cash from all-stock merg­er

3 years ago
Financing
Deals

Hitch­ing a quick ride on the M&A train, As­traZeneca wa­gers $100M cash on T cell en­gager

3 years ago
Deals

Phar­ma re­acts to post-Roe; Drug­mak­ers beef up cy­ber de­fense; Boehringer, Roche qui­et­ly axe drugs; and more

3 years ago
Weekly

Proven­tion's sec­ond shot at FDA ap­proval for di­a­betes pre­ven­tion drug hits new hur­dle

3 years ago
FDA+

Lit­tle biotech makes deep cuts as it strug­gles to get nar­colep­sy drug ap­proved amid months of reg­u­la­to­ry lim­bo

3 years ago
People

Catch­ing up with Bris­tol My­ers and Mer­ck, As­traZeneca de­clares neoad­ju­vant win for PD-L1/chemo com­bo

3 years ago
R&D

Reel­ing from Covid flop, Icosavax says its RSV can­di­date passed ear­ly test. But in­vestors need some more con­vinc­ing

3 years ago
R&D

Jazz re­ports sur­prise PhI­II flop for cannabi­noid drug from $7.2B GW buy­out

3 years ago
R&D

Roivant chops sick­le cell gene ther­a­py, der­ma­tol­ogy drugs to fo­cus on 'high­er val­ue pro­ject­s'

3 years ago
R&D

How pre­pared is bio­phar­ma for the cy­ber dooms­day?

3 years ago
Pharma
In Focus

Roivant un­veils lat­est spin­out as Pfiz­er en­trusts JAK1/TYK2 to Pri­o­vant

3 years ago
Startups

Take­da, Ar­row­head spot­light da­ta from small tri­al show­ing RNAi works in a rare liv­er con­di­tion

3 years ago
R&D

No stranger to gene ther­a­py woes, Astel­las runs in­to an­oth­er safe­ty-re­lat­ed clin­i­cal hold

3 years ago
Cell/Gene Tx
FDA+

15 LGBTQ lead­ers in bio­phar­ma; Paul Stof­fels’ Gala­pa­gos re­vamp; As­traZeneca catch­es up in AT­TR; and more

3 years ago
Weekly

Sanofi, GSK tout 72% Omi­cron ef­fi­ca­cy in PhI­II tri­al of next-gen, bi­va­lent shot — with an eye to year-end roll­out

3 years ago
R&D
Coronavirus

CAR-T in, IPF drug out: Gala­pa­gos bails on biotech part­ner­ship amid pipeline re­vamp

3 years ago
Deals
R&D

Alarmed by side ef­fect, FDA slaps clin­i­cal hold on Sarep­ta's next-gen Duchenne drug

3 years ago
FDA+

No­var­tis pledges $250M in R&D fund­ing for ne­glect­ed trop­i­cal dis­eases, malar­ia

3 years ago
R&D

In pur­suit of ac­ces­si­ble sick­le cell cure, No­var­tis inks $1.5B deal to tap Pre­ci­sion's AR­CUS gene edit­ing tech

3 years ago
Deals
Cell/Gene Tx

Ab­b­Vie walks away from Mor­phic deal in af­ter­math of safe­ty sig­nal in pre­clin­i­cal test­ing

3 years ago
Deals
First page Previous page 28293031323334 Next page Last page
A service from the Financial Times